Anti-microbial/Anti-fungal Tests Market: Local Governments Entering into Partnerships with Manufacturers Helps in the Growth

0
22

Microbial and fungal infections are a major cause of death globally and can even cause potential epidemics, creating a huge economic burden on countries, especially developing ones. To nip the spread of such infections in the bud, prevention is a far better solution than cure – accomplished by isolating infected cases and carrying out primary screening tests. Future Market Insights in its report titled ‘Anti-microbial/Anti-fungal Tests Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027’ has comprehensively analysed the global anti-microbial/ anti-fungal tests market for a decade. The anti-microbial/ anti-fungal tests market is expected to witness a robust CAGR of 6% from 2017 to 2027.

Hospitals and reference labs are the largest end users in the anti-microbial/ anti-fungal tests market by a substantial margin. It has been observed that the global per-capita healthcare spending has doubled because of rising awareness of myriad treatment options and diagnostic tools for detecting and curing various diseases. Reference labs are predicted to grow faster than hospitals in the anti-microbial/ anti-fungal tests market.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5566

The companies profiled in the report are Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories, Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience, Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc.

Leave a Reply